Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 2/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20333177 | 0.97 | NPC1 (0.42) | HPGDNPC1TP53RAB9ATHRA | |
| SCHEMBL20356813 | 0.93 | USP2 (0.37) | HPGDNPC1TP53RAB9ATHRA | |
| SCHEMBL24641404 | 0.92 | THRA (0.39) | HPGDNPC1TP53RAB9ATHRA | |
| SCHEMBL24812062 | 0.92 | HPGD (0.38) | HPGDNPC1TP53RAB9ATHRA | |
| SCHEMBL20333240 | 0.90 | GNAI3 (0.41) | HPGDNPC1TP53RAB9ATHRA | |
| SCHEMBL22861471 | 0.90 | NPC1 (0.40) | HPGDNPC1TP53RAB9ATHRA | |
| SCHEMBL27667664 | 0.90 | GNAI3 (0.40) | HPGDNPC1TP53RAB9ATHRA | |
| SCHEMBL21348141 | 0.87 | THRA (0.39) | HPGDNPC1TP53RAB9ATHRA | |
| SCHEMBL24925694 | 0.87 | LTA4H (0.46) | THRATHRBLTA4HALDH1A1 | |
| SCHEMBL20333193 | 0.86 | LTA4H (0.49) | THRATHRBGNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702429-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230013344-A1 | MTORC MODULATORS AND USES THEREOF | EVOTEC (FRANCE) SAS (FR) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702429-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | HPGD 4020/4885NPC1 1541/4885TP53 1497/4885 |
| US-20230013344-A1 | MTORC MODULATORS AND USES THEREOF | MTOR, RICTOR, RPTOR | HPGD 4020/4885NPC1 1541/4885TP53 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.